TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Warming Comparison of Devices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective open abdominal surgical procedures with an expected duration of 2 to 4 hours and requiring general anesthesia~* American Society of Anesthesiologists(ASA) physical status I-III~* Patient age: \> 18 years and \<80 years~Exclusion Criteria:~* Patient age: \< 18 years and \>80 years~* Patients with break in skin integrity on the extremity selected as the application site~* Patients with history of upper extremity peripheral vascular disease~* Patients with history of allergic skin conditions of the upper extremities~* Patients with history of bleeding disorders/coagulopathy~* Patient with history of malignant hyperthermia~* Patients who are pregnant~* Patient unwilling or unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- vH2 System Group (Type: EXPERIMENTAL): The vital heat vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical. The vital heat vH2 System will be used for patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
- Control Group (Type: ACTIVE_COMPARATOR): The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket. The Bair Hugger System is the site's current approach to patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Fully aware this study and signed the informed consent form in voluntary manner, and willing and able to comply with the study procedure;~2. Age ≥18 years;~3. Histologically diagnosed locally advanced or metastatic NSCLC with MET exon 14 mutation;~4. Cohort 1: disease progression or intolerable toxicity after previous therapy with platinum-based chemotherapeutic regimen (for the patients who have received platinum-based adjuvant chemotherapy/radiotherapy, neoadjuvant chemotherapy/radiotherapy previously or radical radiochemotherapy for progressive disease, if the disease progression occurred \< 6 months after the end of the last therapy, the patient belongs to failure after the first-line therapy); Cohort 2: no any previous systematic antitumor therapy for advanced diseases;~5. Having measurable lesions (in accordance with RECIST 1.1 criteria);~6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1, or Karnofsky performance status ≥80;~7. Survival is expected to exceed 12 weeks;~8. Adequate functionality in bone marrow, liver, kidney~9. Able to take or swallow the drug orally.~10. Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 30 days after discontinuation of the study drug,The male patients whose sexual partners are women of childbearing age must use condom during sexual intercourse during the study and within 6 months after discontinuation of study drug;~Exclusion Criteria:~1. Having gene mutations sensitive to targeted drugs for EGFR, ALK and ROS1;~2. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years. Stage I malignant tumor after radical treatment for at least 3 years, except those considered by investigators to have small possibility of recurrence. Patients with radically treated carcinoma in situ (non-infiltrating) and skin cancer other than malignant melanoma can be enrolled;~3. Having received antitumor therapy (including chemotherapy, hormone therapy, biotherapy, immunotherapy or traditional Chinese medicine for antitumor indication) within 3 weeks prior to the start of study treatment, or having received treatment with small molecular tyrosine kinase inhibitors (e.g., EGFR-TKI) within 2 weeks prior to the start of study treatment;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Savolitinib (Type: EXPERIMENTAL): NSCLC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed primary acute myeloid leukemia (AML)~  * At least 20% bone marrow blasts~ * Meets the customary FAB criteria for AML~    * Patients with cytopenias and bone marrow blasts who do not meet the FAB criteria are eligible provided they have a karyotypic abnormality characteristic of de novo AML (e.g., t\[8;21\], inv16, or t\[16;16\]) OR they have the unequivocal presence of megakaryoblasts~ * Isolated granulocytic sarcoma (myeloblastoma) allowed regardless of the results outlined above~* Previously untreated disease~* No promyelocytic leukemia (FAB M3)~* No documented myelodysplastic syndromes (preleukemia) (e.g., chronic myelomonocytic leukemia, refractory anemia \[RA\], RA with excess blasts, or RA with ringed sideroblasts)~* No juvenile myelomonocytic leukemia~* No Fanconi's anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome~* No Down syndrome~PATIENT CHARACTERISTICS:~Age~* 1 month to 21 years\* NOTE: \*Children under 1 month of age who have progressive disease are allowed~Performance status~* Karnofsky 50-100% (over 16 years of age) OR~* Lansky 50-100% (ages 1 to 16)\* NOTE: Children under 1 year of age do not require a performance status~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* No inadequate liver function~Renal~* No inadequate renal function~* No hyperuricemia (greater than 8.0 mg/dL)~* Creatinine clearance or radioisotope glomerular filtration rate (GFR) at least 70 mL/min OR an equivalent normal GFR OR~* Creatinine no greater than 1.5 times normal~Cardiovascular~* Shortening fraction at least 27% by echocardiogram OR~* Ejection fraction at least 50% by MUGA~Pulmonary~* No proven or suspected pneumonia~Other~* Not pregnant or nursing~* No proven or suspected sepsis or meningitis~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy except intrathecal cytarabine administered that was administered at diagnosis~Endocrine therapy~* Prior topical and inhalation steroids allowed~* No concurrent steroids as antiemetics~Radiotherapy~* No prior radiotherapy~Surgery~* Not specified~Other~* No prior antileukemic therapy~* No concurrent pressor agent or ventilatory support unless approved by the study chair~* No concurrent participation in another COG therapeutic study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Achilles tendon rupture operated on within 96 hours of diagnose.~Exclusion Criteria:~1. Inability or refusal to give informed consent for participation in the study~2. Ongoing treatment with anticoagulant therapy~3. Inability to comply with the study instructions~4. Known kidney disorder~5. Heart failure with pitting oedema~6. Thrombophlebitis~7. Recent thromboembolic event (during the preceding 3 months)~8. Recent surgery (during the preceding month)~9. Presence of known malignancy~10. Current bleeding disorder~11. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Routine care: Plaster Cast Treatment (Type: NO_INTERVENTION): Two weeks of postoperative conventional lower limb plaster cast immobilization in 30 degrees of plantarflexion
- Intermittent pneumatic compression (IPC) (Type: EXPERIMENTAL): Two weeks of calf IPC by Aircast® VenaFlow® Elite System during immobilization in an orthosis Aicast® XP Walker.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage IIIB to IV per American Joint Committee on Cancer \[AJCC\]), or confirmed diagnosis of non-resectable advanced metastatic colorectal cancer (mCRC), or any other indication upon agreement with the Sponsor, whose disease has progressed despite previous antineoplastic therapy or for whom no further effective standard therapy is available~* Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation~* Evidence of measurable disease as determined by RECIST v1.1~* World Health Organization (WHO) Performance Status ≤ 2~* Negative serum pregnancy test within 72 hours prior to the first study dose in all women of childbearing potential~Exclusion Criteria:~Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors~* Symptomatic or untreated leptomeningeal disease~* Symptomatic brain metastases. Patients are not permitted to receive enzyme inducing anti-epileptic drugs~* Known acute or chronic pancreatitis~* History or current evidence of retinal disease, retinal vein occlusion or ophthalmopathy~* Clinically significant cardiac disease~* Patients with abnormal laboratory values at Screening/baseline~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LGX818/MEK162~* Previous or concurrent malignancy~* Pregnant or nursing (lactating) women~* For addition of LEE011 in the triple combination, congenital long QT syndrome or family history of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3, brain metastases at baseline, abnormal coagulation results PT/INR \>1.5 x ULN or aPTT \>1.5 x ULN.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dual combination (Type: EXPERIMENTAL): LGX818 QD and MEK162 BID
- triple combination (Type: EXPERIMENTAL): LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, male or female, 21 to 55 years of age, body weight no less than 55 kg, Body mass index (BMI) of 17.5 to 30.5 kg/m2. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead electrocardiogram (ECG) or clinical laboratory tests.~* An informed consent document signed and dated by the subject.~* Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing), positive Hepatitis B surface antigen or Human Immunodeficiency Virus (HIV) serology results.~* pregnant or nursing female,~* alcohol, drug, smoke user,~* sensitive to any study medication or related component,~* History or active gout,~* History or active tuberculosis,~* Known optic neuritis or other ophthalmological conditions.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1.0 (Type: ACTIVE_COMPARATOR): Test Myrin P Forte Contains 150mg Rifampicin, 75mg Isoniazid, 275mg Ethambutol, 400mg Pyrazinamide
- 2.0 (Type: ACTIVE_COMPARATOR): Reference Single drug reference preparations contain Rifampicin, Isoniazid, Ethambutol, Pyrazinamide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women 18 years of age or older~* Confirmed diagnosis of multiple myeloma(MM) by Durie and Dalmon staging criteria on IV bisphosphonate therapy with either pamidronate or zoledronic acid for 8-12 months~* MM patients in either CR (complete response) or PR (partial response) by EBMT criteria~* ECOG Performance Status of 0-2~Exclusion Criteria:~* MM patients on active anti-MM therapy (maintenance regimens allowed)~* Renal failure with serum creatinine \>2mg/dL and/or creatinine clearance of \<30ml/min~* Relapsed, refractory or progressive disease~* Any condition or situation that, in the opinion of the investigator, may put the subject at significant risk, confound the results of the study, or interfere significantly with the subject's participation in the study~* Hypersensitivity or any contraindication to a single dose of zoledronic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: OTHER): Single arm biomarker study after a single dose of zoledronic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of secondary hyperparathyroidism (iPTH \>200 pg/mL to \<500 pg/mL)~* Serum Ca \< 11.0 mg/dL, and serum P \< 7.0 mg/dL.~* At least one year of regular hemodialysis therapy~Exclusion Criteria:~* Patients with a history of hypersensitivity to any ingredient of maxacalcitol~* Patients who had received parathyroidectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.0 μg/day Alfacalcidol (Type: OTHER): Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months
- 0.25 μg/day Alfacalcidol (Type: OTHER): Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microbial Resistance of Rifaximin in Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- The inclusion criteria~1. cirrhosis due to HCV infection~2. age 18 to 75 years,~3. experiencing at least one episode of OHE,~4. MELD score ≤ 25~Exclusion Criteria:~1. Patients with neurological or communication problems,~2. hepatocellular carcinoma~3. diabetes mellitus~4. active infection~5. serum creatinine \> 2 mg/dl, Hg \< 8 g/dL, serum Na \< 125 mmol/L or serum K \< 2.5 mmol/L .~6. Patients with previous intake of rifaximin as prophylaxis or any antibiotic within the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- interventional (Type: ACTIVE_COMPARATOR): 50 patient take rifaximin plus lactulose for 6 months
- control (Type: PLACEBO_COMPARATOR): 50 patient take lactulose for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - 75, male or non-pregnant female;~2. Stable or unstable angina with evidence of myocardial ischemia, or patient with myocardial infarction;~3. Coronary angiography reveals stenosis lesions;~4. Discovery of ADP induced platelet inhibition rate \< 50% and MAADP \>47mm via thromboelastography (indicating low responsiveness to Clopidogrel with high risk for stent thrombosis formation);~5. Is able to understand the objective of the trial, takes part voluntarily and signs the written informed consent form.~Exclusion Criteria:~1. Those who have participated in other drug or therapy equipment clinical trials but did not reach the main study endpoint time limit;~2. Symptoms of severe heart failure (NYHA Class III and above) or left ventricular ejection fraction \< 40% (ultrasound or left ventricle ngiography);~3. Pregnant or lactating women;~4. severely impaired renal function before surgery: serum creatinine \> 2.0mg/dl;~5. Impaired liver function before surgery: Serum GPT \> 120U/L;~6. Bleeding tendency, history of active peptic ulcer, history of cerebral hemorrhage or cavum subarachnoidale bleeding, patients with antiplatelet agent and anticoagulant treatment contraindications and hence are unable to undergo anticoagulant therapy;~7. Patients who are unable to withstand dual antiplatelet therapy due to allergy to Aspirin, Clopidogrel or ticlopidine, heparin, contrast agent, paclitaxel and metals;~8. Leucocyte \< 3.5 x 109; and/or platelet \< 100,000/mm3 or \> 750,000/mm3;~9. Patient's life expectancy is less than 12 months;~10. Patients who plan to undergo coronary artery bypass grafting or other surgery within 1 year;~11. Those waiting for heart transplant;~12. Patients who are deemed by the researchers to have low compliance and unable to abide by the requirements and complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel + Aspirit (Type: ACTIVE_COMPARATOR): A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
- Clopidogrel + Aspirin (Type: ACTIVE_COMPARATOR): B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
- Clopidogrel + Aspirin + Cilostazol (Type: ACTIVE_COMPARATOR): C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete